Victoria Johnson

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

100% overall response and complete response rates were seen in patients treated with prior CD19 CAR T-cell therapy.

The fourth and final cohort is dosing participants with the highest investigated dose of 3 x 106 cells/kg.

Overall response rate was 41.7% and median progression free survival was 7.2 months.

Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.

The phase 1/2 trial of VX880 remains on clinical hold in the US.

69% of patients followed up for at least 1 year continue to have an ongoing response.

Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.

Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.

Higher-dose lymphodepleting regimens led to higher toxicity but high response rates.

High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.

Review top news and interview highlights from the week ending June 3, 2022.

A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.

Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.

Beti-cel was rated a B+ for lingering questions about durability and unknown risks.

A phase 1 trial evaluated the combination in patients regardless of PD-L1 status and no differences were seen between those negative or positive.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

BioMarin now expects to file in September 2022 instead of June.

Treated patients had significant improvements in fatigue and lymphoma symptoms.

A lower objective response rate in cohort 4 reflected a higher disease burden with a greater number of tumors.

RP-L301 also improved hemolysis and eliminated the need for red blood cell transfusions for up to 1year after therapy.

The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

All study participants met criteria to remain off enzyme replacement therapy through 104 weeks after treatment.

NeoCart was originally developed by the company Histogenics.

A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.

The cell therapy was tolerated although there was a SUSAR of GGT elevations.

The positive opinion was based on findings from studies conducted in Taiwan.

Motor and pulmonary function have stabilized or improved in participants treated with SGT-001.

Investigators from Seattle Children’s Hospital found that engineered T-cell regulatory products demonstrated significant suppression of effector T cells.